|
1.
|
|
15 p, 942.2 KB |
A growth modulation index-based geistra score as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas : A Spanish group for sarcoma research (GEIS) retrospective study
/
Martínez-Trufero, J. (Hospital Universitario Miguel Servet) ;
Sande-González, L.M.D. (Hospital Universitario de Leon) ;
Luna, P. (Hospital Universitario Son Espases) ;
Martin-Broto, J. (Hospital Universitario Virgen del Rocio. Instituto de Biomedicina de Sevilla (IBiS; CSIC. US. HUVR)) ;
Álvarez, R. (Hospital Universitario Gregorio Marañon) ;
Marquina, G. (Hospital Universitario Clinico San Carlos) ;
Diaz-Beveridge, R. (Medical Oncology Department. Hospital Politécnico La Fe) ;
Poveda, A. (Instituto Valenciano de Oncologia) ;
Cano, J.M. (Hospital General de Ciudad Real) ;
Cruz-Jurado, J. (Hospital Universitario Canarias) ;
López-Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Salgado, M.A.V. (Hospital Universitario Ramon y Cajal. RYCIS. CIBERONC) ;
Valverde-Morales, C.M. (Hospital Universitari Vall d'Hebron) ;
Sevilla, I. (Universitarios Regional y Virgen de la Victoria de Málaga) ;
Martínez-García, J. (Hospital Virgen de la Arrixaca) ;
Rubio-Casadevall, J. (Instituto Catalan Oncologia) ;
Juan, A.D. (Hospital Marqués de Valdecilla) ;
Carrasco, J.A. (Hospital Alvaro Cunqueiro) ;
Moura, D.S. (Instituto de Biomedicina de Sevilla (IBiS; CSIC. US. HUVR)) ;
Gurruchaga-Sotes, I. (Hospital Universitario Miguel Servet) ;
Gutiérrez, A. (Hospital Universitario Son Espases)
The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. [...]
2021 -  10.3390/cancers13040792
Cancers, Vol. 13 Núm. 4 (february 2021) , p. 1-15
|
|
|
2.
|
|
13 p, 2.3 MB |
A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy
/
Rubinstein, Tammi Arbel (Institute of Oncology, Tel Aviv Sourasky Medical Center) ;
Reuveni, Inbal (Institute of Oncology, Tel Aviv Sourasky Medical Center) ;
Hesin, Arkadi (Institute of Oncology, Tel Aviv Sourasky Medical Center) ;
Klein-Goldberg, Anat (Institute of Oncology, Tel Aviv Sourasky Medical Center) ;
Olauson, Hannes (Karolinska Institutet. Department of Clinical Science, Intervention and Technology) ;
Larsson, Tobias E. (Karolinska University Hospital. Department of Nephrology) ;
Abraham, Carmela R. (Boston University School of Medicine. Department of Biochemistry) ;
Zeldich, Ella (Boston University School of Medicine. Department of Biochemistry) ;
Bosch i Merino, Assumpció (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Chillón Rodríguez, Miguel (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Hollander, Kenneth Samuel (Institute of Oncology, Tel Aviv Sourasky Medical Center) ;
Shabtay-Orbach, Ayelet (Institute of Oncology, Tel Aviv Sourasky Medical Center) ;
Vainer, Gilad W. (Pathology Institute, Tel Aviv Sourasky Medical Center) ;
Wolf, Ido (Institute of Oncology, Tel Aviv Sourasky Medical Center) ;
Rubinek, Tami (Institute of Oncology, Tel Aviv Sourasky Medical Center)
Klotho is an anti-aging transmembrane protein, which can be shed and can function as a hormone. Accumulating data indicate that klotho is a tumor suppressor in a wide array of malignancies, and designate the subdomain KL1 as the active region of the protein towards this activity. [...]
2021 - 10.3390/cancers13246297
Cancers, Vol. 13 Núm. 24 (2021) , p. 6297
|
|
|
3.
|
|
25 p, 2.5 MB |
Advances in preclinical/clinical glioblastoma treatment : can nanoparticles be of help?
/
Ruiz-Molina, Daniel (Institut Català de Nanociència i Nanotecnologia) ;
Mao, Xiaoman (Institut Català de Nanociència i Nanotecnologia) ;
Alfonso, Paula (Institut Català de Nanociència i Nanotecnologia) ;
Lorenzo Rivera, Julia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Bruna, Jordi (Institut d'Investigació Biomèdica de Bellvitge) ;
Yuste Mateos, Víctor J. (Víctor José) (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Novio Vázquez, Fernando (Universitat Autònoma de Barcelona. Departament de Química)
Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. [...]
2022 - 10.3390/cancers14194960
Cancers, Vol. 14, issue 19 (Oct. 2022) , art. 4960
|
|
|
4.
|
|
22 p, 2.7 MB |
Somatic hypomethylation of pericentromeric sst1 repeats and tetraploidization in human colorectal cancer cells
/
González Fernández, Beatriz (Institut Germans Trias i Pujol) ;
Navarro Jiménez, Maria (Institut Germans Trias i Pujol) ;
Alonso De Gennaro, María José (Institut Germans Trias i Pujol) ;
Jansen, Sanne Marcia (Institut Germans Trias i Pujol) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Perucho, Manuel (Sanford Burnham Prebys Medical Discovery Institute (SBP)) ;
Alonso, Sergio (Institut Germans Trias i Pujol)
Somatic DNA hypomethylation and aneuploidy are hallmarks of cancer, and there is evidence for a causal relationship between them in knockout mice but not in human cancer. The non-mobile pericentromeric repetitive elements SST1 are hypomethylated in about 17% of human colorectal cancers (CRC) with some 5-7% exhibiting strong age-independent demethylation. [...]
2021 - 10.3390/cancers13215353
Cancers, Vol. 13 Núm. 21 (11-1 2021) , p. 5353
|
|
|
5.
|
|
|
6.
|
|
12 p, 900.5 KB |
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
/
García Fortes, María (Universidad de Málaga) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Álvarez Larrán, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Raya, José M. (Hospital Universitario de Canarias (La Laguna)) ;
Angona, Anna (Hospital del Mar (Barcelona, Catalunya)) ;
Estrada, Natalia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ;
Cuevas, Beatriz (Hospital Universitario de Burgos) ;
García Hernández, María C. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Gomez Casares, Maria Teresa (Hospital Universitario Doctor Negrín) ;
Ferrer Marín, Francisca (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Saavedra, Silvana (Institut d'Investigació Biomèdica Sant Pau) ;
Cervantes, Francisco (Hospital Clínic i Provincial de Barcelona) ;
García Delgado, Regina (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). [...]
2022 - 10.3390/cancers14092331
Cancers, Vol. 14 Núm. 9 (5-1 2022) , p. 2331
|
|
|
7.
|
|
18 p, 886.7 KB |
Cancer Survival in Adults in Spain : A Population-Based Study of the Spanish Network of Cancer Registries (REDECAN)
/
Guevara, Marcela (Instituto de Investigación Sanitaria de Navarra) ;
Molinuevo, Amaia (Biodonostia Health Research Institute) ;
Salmerón, Diego (Departamento de Ciencias Sociosanitarias. IMIB-Arrixaca. Universidad de Murcia) ;
Marcos-Gragera, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Carulla, Marià (Faculty of Medicine and Health Sciences. Rovira i Virgili University) ;
Chirlaque, María-Dolores (Murcia Regional Health Council) ;
Rodríguez Camblor, Marta (Public Health Directorate of Asturias) ;
Alemán, Araceli (Canary Health Service) ;
Rojas, Dolores (Canary Health Service) ;
Vizcaino Batllés, Ana (Generalitat Valenciana) ;
Chico, Matilde (Health and Social Welfare Authority (Ciutat Real)) ;
Jiménez Chillarón, Rosario (Health and Social Welfare Authority (Conca)) ;
López de Munain, Arantza (Basque Country Health Department) ;
de Castro, Visitación (Basque Country Health Department) ;
Sánchez, María-José (Universidad de Granada) ;
Ramalle-Gómara, Enrique (La Rioja Regional Health Authority) ;
Franch, Paula (Balearic Islands Public Health Department) ;
Galceran, Jaume (Universitat Rovira i Virgili) ;
Ardanaz, Eva (Instituto de Investigación Sanitaria de Navarra) ;
Universitat Autònoma de Barcelona
The assessment of cancer survival at the population level is essential for monitoring progress in cancer control. We aimed to assess cancer survival and its trends in adults in Spain. Individual records of 601,250 adults with primary cancer diagnosed during 2002-2013 and followed up to 2015 were included from 13 population-based cancer registries. [...]
2022 - 10.3390/cancers14102441
Cancers, Vol. 14 Núm. 10 (5-2 2022) , p. 2441
|
|
|
8.
|
|
|
9.
|
|
21 p, 3.2 MB |
Real-World Data on Chronic Myelomonocytic Leukemia : Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes
/
Castaño-Díez, Sandra (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
López-Guerra, Mónica (Centro de Investigación Biomédica en Red de Cáncer) ;
Bosch-Castañeda, Cristina (Universitat de Barcelona) ;
Bataller, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Charry, Paola (Hospital Clínic i Provincial de Barcelona) ;
Esteban, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Guijarro, Francesca (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez-Vicente, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Castillo-Girón, Carlos (Hospital Clínic i Provincial de Barcelona) ;
Cortes, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez-Roca, Alexandra (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Triguero, Ana (Hospital Clínic i Provincial de Barcelona) ;
Álamo, José Ramón (Hospital Clínic i Provincial de Barcelona) ;
Bea, Sílvia (Centro de Investigación Biomédica en Red de Cáncer) ;
Costa, Dolors (Centro de Investigación Biomédica en Red de Cáncer) ;
Colomer, Dolors (Centro de Investigación Biomédica en Red de Cáncer) ;
Rozman, María (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Esteve Reyner, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díaz-Beyá, Marina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Despite emerging molecular information on chronic myelomonocytic leukemia (CMML), patient outcome remains unsatisfactory and little is known about the transformation to acute myeloid leukemia (AML). In a single-center cohort of 219 CMML patients, we explored the potential correlation between clinical features, gene mutations, and treatment regimens with overall survival (OS) and clonal evolution into AML. [...]
2022 - 10.3390/cancers14174107
Cancers, Vol. 14 Núm. 17 (september 2022), p. 4107
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
